Home bam

Cardiometabolic Science

The Cardiometabolic Science Theme encompasses research into obesity, diabetes, cardiovascular risk, metabolic syndrome/insulin resistance, cardiovascular physiology and disease, vascular cell biology, microangiopathies, as well as related clinical trials.

The Theme involves members of the UCL community from the Institute of Cardiovascular Science, the SLMS Divisions and Institutes, and reaches out across the wider UCL expertise to facilitate cutting-edge health science research and delivery.

Therapeutic Innovation in Inherited Cardiovascular Conditions Symposium 2018

On Friday 8 June 2018, 150 researchers from across UCL and beyond were brought together for the third joint meeting between UCL, Queen Mary University of London and Barts Health NHS Trust, dedicated to rare and inherited cardiovascular disease. 

There are between 6,000 and 8,000 known rare disorders and it is estimated that a rare disease will affect 1 in 17 of the European population at some point in their lives. Many of these disorders primarily affect the cardiovascular system or, as in the case of rare metabolic and neurological conditions, are characterised by cardiovascular involvement that is the major determinant of prognosis and quality of life.

The Symposium was designed to showcase translational research in rare cardiovascular disease and to catalyse interaction between scientists, clinicians and patient representatives. The focus this year was on therapeutic innovation and we were delighted to welcome internationally renowned experts and young clinician scientists to present the current state of the art and cutting edge research in novel therapies.

We are grateful to our industrial partners at Sanofi Genzyme and Pfizer for supporting the event.

Eminent speakers presented their ground-breaking work, including:

  • Dr Robert McDowell (MyoKardia) - Actin-myosin modulation in HCM and DCM  
  • Dr Giulia Mearini (University Medical Center Hamburg-Eppendorf) - Correction of Haploinsufficiency
  • Professor Calum Macrae (Brigham and Women’s Hospital; and Harvard Medical School) - Treating Laminopathy
  • Professor Perry Elliott (UCL Institute of Cardiovascular Science and Barts Heart Centre) Hypertrophic cardiomyopathy 
  • Dr Karim Wahbi (University of Paris Descartes, France) - Laminopathies
  • Professor David Spiegelhalter (University of Cambridge) Want to communicate the potential benefits and harms of treatments? Start by listening to patients      
  • Professor Axel Bauer (Ludwig-Maximilians-University Munich, Germany) ECG and autonomic markers to predict sudden death
  • Professor Alexander Gourine (UCL Neuroscience, Physiology and Pharmacology) Neuromodulation in the treatment of arrhythmia
  • Professor Pier Lambiase (UCL and Barts Heart Centre) - Early Repolarisation: current concepts and challenges
  • Professor Aleš Linhart (Charles University in Prague) New treatment options for cardiac disease in Fabry Disease
  • Professor Stephane Heymans (Maastricht University Medical Centre) - Immunosuppressive therapy in patients with virus-negative non-fulminant inflammatory cardiomyopathy
  • Professor Claudio Rapezzi (University of Bologna, Italy) - Novel approaches to diagnosis and treatment of TTR amyloidosis


Below is the link to a list of researchers who are currently working in the field of cardiometabolic science research at UCL. Follow the link to find their contact details and more information about their work.

Cardiometabolic Science